Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.38 |
| ▸ | TK2 | O00142 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342615 | 0.90 | TK1 (0.39) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL3397223 | 0.88 | TK1 (0.39) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL13387567 | 0.88 | TK1 (0.44) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL6753364 | 0.88 | TK1 (0.41) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL2877649 | 0.85 | TK1 (0.43) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL8053437 | 0.84 | TK1 (0.42) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL28182722 | 0.84 | TK2 (0.46) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL28190357 | 0.83 | TK2 (0.47) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL7608037 | 0.82 | TK1 (0.36) | TK1TK2ALDH1A1LMNAALB | |
| SCHEMBL27878939 | 0.81 | TYMP (0.46) | TK1TK2ALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390536-A1 | ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1377595-A2 | ANTISENSE MODULATION OF HISTONE DEACETYLASE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002088393-A1 | ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1248794-A1 | ANTISENSE MODULATION OF SMAD7 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002050244-A2 | ANTISENSE MODULATION OF HISTONE DEACETYLASE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002020550-A1 | ANTISENSE MODULATION OF MEKK3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001053313-A1 | ANTISENSE MODULATION OF SMAD7 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |